NASH Affects Millions, But the Future for Treatment Remains Brighter Than Ever
Managing NASH/MASH is becoming more promising with new advancements. The recent FDA approval of resmetirom, which offers hope for those with moderate-to-advanced liver scarring, marks a breakthrough in treatment. GLI’s Jeff McIntyre discussed the current landscape with Pharmacy Times. As new therapies move down the development pipeline, pharmacists are pivotal in guiding patients, promoting healthy lifestyle changes, and supporting initiatives that enhance liver disease care. With increasing treatment options and growing awareness, the future looks bright.
New Therapies to Stop Liver Aging?
A new study in Nature Aging suggests it may be possible to reverse some aging-related liver damage and partially restore liver health. Researchers identified genes causing cell death in older liver cells and found that treating aged mice with Ferrostatin-1 improved liver cell health, which merits investigation as a potential therapy for NAFLD.
Poor Sleep Linked to Higher Risk of MAFLD
In a cross-sectional study of over 10,000 adults in Xinjiang, China, nearly 40% had MAFLD. Poor sleep and lack of physical activity were strongly linked to a higher risk of MAFLD, with the highest risk seen in those with both poor sleep and no exercise. Improving sleep quality was more effective at reducing MAFLD risk than increasing physical activity, highlighting the need for public health strategies that address both sleep and exercise.
Positive Relationship Between SII and NAFLD Risk
A recent study found that higher systemic immune-inflammation index (SII) levels are associated with a greater risk of NAFLD in American teens. Variables of the SII from blood test labs like ALT, triglycerides, and BUN help explain this link. NAFLD arises from a mix of genetic, environmental, and metabolic factors, with inflammation and insulin resistance playing key roles.
Upcoming Events
September 13-16, 2024: GLI’s Advanced Advocacy Academy (A3)
We’re excited to announce that GLI will be participating at these upcoming conferences:
- September 5-6, 2024: Paris MASH Meeting
- September 24-26, 2024: 8th Annual MASH Drug Development Summit
- October 15-16, 2024: Reuters Pharma & Patient USA 2024
- October 24-25, 2024: MOSAIC – Global NASH/MASH Trialist Forum
- November 15-19, 2024: AASLD’s The Liver Meeting
Email us at info@globalliver.org to set up a meeting
